In yesterday’s session, the market changed course to erase earlier gains, dragging the major indices into negative territory for the week. The Nasdaq led yesterday’s declines with a 2.51% loss. Earnings season officially begins today, with several big banks reporting to cap off the week. Let’s see if the banks can inspire yet another turnaround before closing bell.
“Big Tech stocks are selling off so dramatically as a product of, ‘yes U.S. rates are likely to go up further this year,’ but also as investors rotate into value and cyclical trades,” said Ed Moya, senior market analyst at Oanda.
Today we’re highlighting a value name that is likely to do well in the coming months, regardless of whether the bulls will steer the ship in 2022.
Palm Beach Group:
Teeka: “Buy this Ticker ASAP” – DONT USE.
With experts projecting gains as high as 1,530% by the end of this year… Anyone who doesn’t buy this ticker will most likely regret it later. Even Forbes has confirmed that when all is said and done, “a new class of millionaires may emerge.” Unfortunately, a recent study shows that only 3% of retirees have invested in this opportunity. That means most people will miss out. Don’t be one of them. Click here and get the ticker now… no strings attached. [REVEAL TICKER]
CVS Health Corporation (CVS). The pharmacy innovation company recently outlined its long-term growth strategy at its 2021 Investor Day, aiming at capitalizing on the significant market opportunity to make healthcare more convenient, personalized, and affordable for consumers. The company will optimize the retail portfolio to serve as community health destinations by closing nearly 900 stores over the next three years to reduce store density and ensure it has the right kinds of stores in suitable locations for consumers and the business.
Moreover, CVS Health is driving a digital-first, technology-forward approach to expand its reach and engagement with its more than 35 million online members. The company will also enhance omnichannel health services to meet the needs of consumers as and when required.
For 2021, the company projects total revenues of at least $290.30 billion. The company’s adjusted earnings per share (EPS) is expected to be at least $8.00. Cash flow from operations is expected to be at least $13.50 billion.
CVS Health also presented a long-term outlook and growth targets. As part of its long-term growth trajectory, the company targets a return to low double-digit adjusted EPS growth in 2024 and beyond.
Goldman Sachs analyst Nathan Rich recently initiated coverage of CVS with a Buy rating and $121 price target. The analyst started the U.S. Managed Care sector with a positive outlook and sees potential for 13% annual earnings growth for the large-cap names over the next two years. He sees “under-appreciated optionality” in CVS’s new provider-focused strategy, with leverage to the value-based care theme and “strong” underlying fundamentals.
Where to invest $1,000 right now...
Before you consider buying CVS, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not CVS.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
The U.S. Economy is headed for trouble…
Why are stocks absolutely soaring right now…? Yet at the same time millions of Americans are out of work… Commercial bankruptcies are piling up… Delinquent credit card debt is skyrocketing… Not to mention, we are smack in the middle of a pandemic that has all but forced our economy to a grinding halt… Something’s just not adding up. Friend, if you are confused by all of this… You are not alone… [Full Story]